Edition:
India

Radius Health Inc (RDUS.OQ)

RDUS.OQ on NASDAQ Stock Exchange Global Market

33.74USD
19 Apr 2018
Change (% chg)

$-1.37 (-3.90%)
Prev Close
$35.11
Open
$34.86
Day's High
$34.90
Day's Low
$33.46
Volume
251,206
Avg. Vol
283,403
52-wk High
$49.15
52-wk Low
$24.68

Chart for

About

Radius Health, Inc. is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company's lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosi... (more)

Overall

Beta: 1.31
Market Cap(Mil.): $1,686.22
Shares Outstanding(Mil.): 43.50
Dividend: --
Yield (%): --

Financials

BRIEF-Radius Health Initiates Phase 3 Trial Of Abaloparatide Injection For Male Osteoporosis

* RADIUS HEALTH INITIATES PHASE 3 CLINICAL TRIAL OF ABALOPARATIDE INJECTION FOR THE TREATMENT OF MALE OSTEOPOROSIS Source text for Eikon: Further company coverage:

31 Mar 2018

BRIEF-Radius Health Provides Update On CHMP Opinion For Abaloparatide-SC

* RADIUS HEALTH PROVIDES UPDATE ON CHMP OPINION FOR ABALOPARATIDE-SC

22 Mar 2018

BRIEF-Radius Health Reports Q4 Loss Per Share $1.59

* RADIUS HEALTH REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS AND PROVIDES BUSINESS UPDATE

02 Mar 2018

BRIEF-Radius Health Expects CHMP To Issue Opinion Regarding Marketing Authorization Application Of Abaloparatide-Sc during H1 2018

* RADIUS HEALTH ANNOUNCES THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) WILL ISSUE A THIRD DAY-180 LIST OF OUTSTANDING ISSUES IN ITS REGULATORY REVIEW OF ABALOPARATIDE-SC, A BONE BUILDING AGENT FOR THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT INCREASED RISK OF FRACTURE

15 Dec 2017

BRIEF-Point72 Asset Management Reports 5.1 Percent Passive Stake In Radius Health

* POINT72 ASSET MANAGEMENT, L.P REPORTS 5.1 PERCENT PASSIVE STAKE IN RADIUS HEALTH INC AS OF NOVEMBER 24, 2017 - SEC FILING‍​ Source text: (http://bit.ly/2iXLIQS) Further company coverage:

28 Nov 2017

BRIEF-Radius Health reports Q3 loss per share $1.31

* Radius Health Inc reports third quarter 2017 financial and operating results and provides business update

03 Nov 2017

Earnings vs. Estimates